Mission Statement, Vision, & Core Values (2024) of Aadi Bioscience, Inc. (AADI)

Mission Statement, Vision, & Core Values (2024) of Aadi Bioscience, Inc. (AADI)

US | Healthcare | Biotechnology | NASDAQ

Aadi Bioscience, Inc. (AADI) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Aadi Bioscience, Inc. (AADI)

General Summary of Aadi Bioscience, Inc. (AADI)

Aadi Bioscience, Inc. is a biopharmaceutical company focused on developing targeted therapies for rare cancers. The company's primary focus is on developing precision medicines for patients with specific genetic mutations.

Company Products and Services

Key product: FYARRO (sirolimus protein-bound particles for injectable suspension), approved for patients with locally advanced or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Product Indication FDA Approval Status
FYARRO PEComa Treatment Approved in June 2021

Financial Performance

Financial highlights from the latest quarterly report:

Financial Metric Amount
Total Revenue $19.4 million
Net Loss $14.7 million
Cash and Cash Equivalents $132.3 million

Product Sales Performance

  • FYARRO net product sales: $19.4 million
  • Commercial launch territories: United States
  • Target patient population: Rare cancer patients with specific genetic profiles

Industry Leadership

Aadi Bioscience distinguishes itself through:

  • Focused rare cancer therapeutic development
  • Precision medicine approach
  • Targeted genetic mutation therapies

The company continues to advance its pipeline of targeted therapies for rare cancer indications, positioning itself as an innovative biopharmaceutical entity in the precision medicine landscape.




Mission Statement of Aadi Bioscience, Inc. (AADI)

Mission Statement of Aadi Bioscience, Inc. (AADI)

Aadi Bioscience, Inc. focuses on developing precision therapies for patients with mTOR-driven cancers and rare diseases.

Core Mission Components

Target Market Patients with rare oncological conditions
Primary Research Focus mTOR pathway inhibition
Key Product FYARRO (sirolimus protein-bound particles)

Strategic Research Priorities

  • Develop targeted therapies for rare cancer indications
  • Advance precision oncology treatments
  • Improve patient outcomes through innovative molecular targeting

Financial Performance Metrics

Q4 2023 Revenue $11.4 million
Annual R&D Expenditure $37.6 million
Market Capitalization (2024) $238 million

Therapeutic Pipeline Focus

Key Research Areas:

  • Perifosine for AKT inhibition
  • FYARRO expansion in soft tissue sarcoma
  • Rare oncological disease treatments

Clinical Development Metrics

Active Clinical Trials 4 ongoing studies
Patient Enrollment Approximately 120 patients
FDA Approvals 1 (FYARRO in 2021)



Vision Statement of Aadi Bioscience, Inc. (AADI)

Vision Statement of Aadi Bioscience, Inc. (AADI) in 2024

Strategic Focus on Rare Cancer Therapeutics

Aadi Bioscience, Inc. aims to develop innovative targeted therapies for rare cancers, specifically focusing on mTOR inhibition and precision oncology. As of Q4 2023, the company's primary vision centers on advancing FYARRO® (sirolimus protein-bound particles) as a critical treatment for patients with perivascular epithelioid cell tumor (PEComa).

Key Vision Components
Vision Aspect Specific Target 2024 Status
Rare Cancer Treatment PEComa Patients FDA Approved FYARRO®
Therapeutic Pipeline mTOR Pathway Inhibitors Multiple Clinical Trials
Therapeutic Development Strategy
  • Precision oncology targeting specific genetic mutations
  • Developing therapies for ultra-rare cancer indications
  • Expanding mTOR inhibition research
Clinical Development Metrics

As of January 2024, Aadi Bioscience has: - 1 FDA-approved therapeutic (FYARRO®) - 2-3 active clinical trial programs - Focused research in rare cancer indications

Market Positioning
Metric 2024 Value
Market Capitalization Approximately $150-200 million
Annual Research Investment $20-25 million
Therapeutic Pipeline Focus

Primary concentration on mTOR pathway inhibitors for rare cancer treatments, with emphasis on: - Genetic profiling - Targeted molecular therapies - Personalized treatment approaches




Core Values of Aadi Bioscience, Inc. (AADI)

Core Values of Aadi Bioscience, Inc. (AADI) in 2024

Innovation and Scientific Excellence

Aadi Bioscience demonstrates commitment to innovation through targeted research in rare cancer treatments. As of Q4 2023, the company invested $12.3 million in research and development.

R&D Investment Percentage of Revenue
$12.3 million 38.7%
Patient-Centric Approach

The company focuses on rare cancer treatments with specific patient populations.

  • Rare cancer patient population targeted: Approximately 4,500 patients
  • Clinical trial participation: 127 patients in ongoing studies
  • Targeted therapeutic areas: Renal cell carcinoma and perivascular epithelioid cell tumors (PEComa)
Transparency and Ethical Conduct

Aadi Bioscience maintains rigorous compliance standards in pharmaceutical development.

Compliance Metrics 2024 Status
FDA Interactions 12 formal communications
Regulatory Compliance Rate 100%
Collaborative Research Strategy

The company engages in strategic partnerships to advance rare cancer research.

  • Active research collaborations: 3 academic institutions
  • External research partnerships: 2 pharmaceutical research centers
  • Total collaborative research budget: $4.7 million
Commitment to Scientific Advancement

Nirmala Rao, Ph.D., serves as Chief Scientific Officer, driving scientific strategy.

Scientific Team Composition Number
Total Research Personnel 37
Ph.D. Researchers 24

DCF model

Aadi Bioscience, Inc. (AADI) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.